Drugs / STM 434
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02262455 | Oct 2014 → Jan 2017 | endometrial cancer, fallopian tube cancer, ovarian cancer | Santa Maria Biotherapeutics | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-10-22 | Atara Biotherapeutics | Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor atarabio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STM 434 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02262455 ↗ |
| Action | Inhibit | “STM 434 (an inhibitor of activin A)” NCT02262455 ↗ |
| Modality | Protein / enzyme biologic | “STM 434, an Activin Type 2B Receptor Fc Fusion” NCT02262455 ↗ |
| Route | Intravenous | “STM 434 will be administered by IV injection.” NCT02262455 ↗ |